X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be utilized to progress the clinical development of CTIM-76, currently under evaluation in early-stage clinical trials for treating CLDN6-positive ovarian tumors, lung tumors, and testicular tumors.
Lead Product(s): CTIM-76
Therapeutic Area: Oncology Product Name: CTIM-76
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nextech
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 02, 2024
Details:
CTIM-76 is a Claudin 6 x CD3 T cell engaging bispecific antibody, which is currently being evaluated for the treatment of patients with CLDN6-positive gynecologic and testicular cancers.
Lead Product(s): CTIM-76
Therapeutic Area: Oncology Product Name: CTIM-76
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2024
Details:
CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. It is being evaluated for the treatment of Claudin 6-Positive gynecologic and testicular cancers.
Lead Product(s): CTIM-76
Therapeutic Area: Oncology Product Name: CTIM-76
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
CTIM-76, is a CLDN6 x CD3 bispecific antibody that incorporates a highly selective CLDN6 binding arm and a CD3 binding single-chain Fv domain in an IgG format. It is is potent with specific lysis of CLDN6+ cancer cells over normal cells.
Lead Product(s): CTIM-76
Therapeutic Area: Oncology Product Name: CTIM-76
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
ONA-XR (onapristone) is a selective progesterone receptor (PR) antagonist designed to block both ligand dependent and ligand-independent activity of PR which downregulates cancer stem cellmobilization, and blocking immune evasion.
Lead Product(s): Onapristone,Anastrozole
Therapeutic Area: Oncology Product Name: ONA-XR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
Under the agreement, Lonza will support the development and manufacturing of CTIM-76, a CLDN6 x CD3 bispecific antibody clinical candidate. The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6.
Lead Product(s): CTIM-76
Therapeutic Area: Oncology Product Name: CTIM-76
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lonza Inc & Lonza America Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 09, 2023
Details:
ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor (PR) that is orally administered. Currently, there are no approved therapies that selectively target PR+ cancers.
Lead Product(s): Onapristone,Fulvestrant
Therapeutic Area: Oncology Product Name: ONA-XR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6) positive cancers.
Lead Product(s): CTIM-76
Therapeutic Area: Oncology Product Name: CTIM-76
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Integral Molecular
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor (PR) that is orally administered. Preclinical and clinical data suggest that ONA-XR has anticancer activity by inhibiting progesterone receptor binding to chromatin.
Lead Product(s): Onapristone,Fulvestrant
Therapeutic Area: Oncology Product Name: ONA-XR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor (PR) that is orally administered. ONA-XR is an investigational drug that has not been approved for marketing by any regulatory authority.
Lead Product(s): Onapristone,Letrozole,Palbociclib
Therapeutic Area: Oncology Product Name: ONA-XR
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Menarini Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
